A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

Arthritis and Rheumatism

Volumn 41, Issue 2, 1998, Pages 335-343

  Davis Jr , John C ^a,c   Austin III, Howard ^b   Boumpas, Dimitrios ^a   Fleisher, Thomas A ^c   Yarboro, Cheryl ^a   Larson, Anna ^d   Balow, James ^b   Klippel, John H ^a   Scott, Dorothy ^d  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; CLADRIBINE; COTRIMOXAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULONEPHRITIS; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEMORY CELL; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SINUSITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; CLADRIBINE; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 0031935284     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O     Document Type: Article

References (45)

1. Davis JC, Tassiulas IO, Boumpas DT. Lupus nephritis. Curr Opin Rheumatol 1996;8:415-23.
2. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3:107-12.
3. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996;125:549-57.
4. Boumpas DT, Austin HA, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
5. Donadio JV Jr, Holley KE, Ilstrup DM. Cytotoxic drug treatment of lupus nephritis. Am J Kidney Dis 1982;2 Suppl 1:178-81.
6. Boumpas DT, Fessier BJ, Austin HA, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2. Dermatologie and joint diseases, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995;123:42-53.
7. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
8. Donadio JV Jr, Glassock RJ. Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993;21:239-50.
9. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-73.
10. Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW Jr, Robins RK, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 1980;77:6865-9.
11. Piro LD. Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Semin Hematol 1996;33:34-9.
12. Saven A. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin Hematol 1996;33:28-33.
13. Nelson MC, Hogan DK. The role of cladribine in the treatment of lymphoid malignancies. Oncol Nurs Forum 1995;22:1395-400.
14. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138-42.
15. Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenstrom's disease with cladribine. Arbeitsgemeinshaft Medikamentos Tumortherapie. Ann Hematol 1997;74:7-10.
16. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeocyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996;7:373-9.
17. Hoffman MA. Cladribine for the treatment of indolent non-Hodgkin's lymphomas. Semin Hematol 1996;33:40-4.
18. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993;81:597-601.
19. Carson DA, Wasson DB, Beutler E. Anti-leukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci U S A 1984;81:2232-6.
20. Guchelaar HJ, Richel DJ, Schaafsma MR. Clinical and toxicological aspects of the anti-neoplastic drug cladribine: a review. Ann Hematol 1994;69:223-30.
21. Seto S, Carrera CJ, Wasson DB, Carson DA. Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes. Adv Exp Med Biol 1986;195:577-82.
22. Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol 1991;309A:15-8.
23. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, et al. Induction apopotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993;81:143-50.
24. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladrabine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13.
25. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996;33:45-52.
26. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996;93:1716-20.
27. Eibschutz B, Baird SM, Weisman MH, Amox DG, Spellman M, Piacquadio D, et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis: a preliminary report. Arthritis Rheum 1995;38:1604-9.
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
29. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
30. Gause WC, Adamovicz J. The use of the PCR to quantitate gene expression. PCR Methods Appl 1994;3:S123-35.
31. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. Elevated Th1-or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: modulation by treatment with anti-ICAM-1 correlated with clinical benefit. J Immunol 1995;155: 5029-37.
32. Mackall CL, Fleisher TA, Brown MR, Andrick MP, Chen CC. Feuerstein IM, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143-9.
33. Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ. Marrow suppression produced by repeated doses of cladribine. Acta Haematol 1994;91:10-5.
34. Grieb P, Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients. Arch Immunol Ther Exp (Warsz) 1995;43:323-7.
35. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991;147:117-23.
36. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
37. Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37:1647-55.
38. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-85.
39. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
40. Flescher E, Fossum D, Ballester A, Maizel A, Sharma S, Talal N. Characterization of B cell growth in systemic lupus erythematosus: effects of recombinant 12-kDa B cell growth factor, interleukin 4, and transforming growth factor-beta. Eur J Immunol 1990;20: 2425-30.
41. Davis J, Fessier BJ, Tassiulas IO, McInnes IB, Yarboro CH, Pillemer S, et al. High-dose versus low-dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. Submitted for publication.
42. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992;63:10-2.
43. Tsokos GC. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1995;7:376-83.
44. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10:1514-8.
45. Juliusson G, Christiansen I, Hansen MM, Jonhson S, Kimby E, Elmhorn-Rosenborg A, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996;14:2160-6.